STEAP1 Full-Length Nanodisc Proteins, Domain Proteins and Stable Cell Lines

Six-transmembrane prostate epithelial antigen 1 (STEAP1), also known as PRSS2 or STEA1, belongs to the six-transmembrane prostate epithelial antigen (STEAP) family, which also includes members STEAP1B, STEAP2, STEAP3, and STEAP4. Among them, STEAP1B is a truncated homolog of STEAP1 and a four-transmembrane protein. STEAP1-4 are metalloproteases that play an important role in iron and copper homeostasis. STEAP1 is a six-pass membrane protein with relatively restricted expression in many normal tissues and elevated expression in prostate cancer and selected other solid tumors. It localizes primarily to the plasma membrane and cell-cell junctions and has been implicated in cellular communication, ion-related processes, and redox biology, although its complete physiological role remains under investigation. Unlike several other STEAP-family proteins, STEAP1 lacks a full intracellular metalloreductase domain. Its tumor-associated surface expression and multi-pass topology have made it an attractive target for antibodies, ADCs, T-cell engagers, engineered cell therapies, and radioligand approaches. More STEAP1 mechanism of action and clinical research progress >>

DIMA BIOTECH provides full-length STEAP1 in Synthetic Nanodisc, cell-free Nanodisc, and detergent formats for native-conformation antibody screening, SPR/BLI, binding characterization, and specificity analysis. Full and terminal-region recombinant proteins provide complementary tools for ELISA, immunization, and epitope mapping. Reference antibodies and conjugated formats support flow cytometry and candidate benchmarking, while a STEAP1-overexpressing 293T stable cell line enables FACS and cell-binding studies. In addition, to accelerate the development of STEAP1 biotherapy, DIMA BIOTECH has also prepared a single B cell seed bank for the GPR75 target, and lead antibody molecules can be obtained in as fast as 28 days.